Asgard Therapeutics
Swedish biotech company exploring reprogramming as the next leap forward in cancer immunotherapy
Sweden
25 employees
Series A
Total: $36.00M
Biotechnology, Health and Wellness
General Information
Get notified when Asgard Therapeutics moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Asgard Therapeutics
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
Sweden Market
Biotechnology
About Asgard Therapeutics
Taxonomy: biotech, cancer immunotherapy, cell reprogramming, gene therapy, immune responses, antigen presenting cells, personalized medicine, biological technology, oncology, start-up, investor-backed, Lund University, TrojanDC technology, Novo Holdings, Boehringer Ingelheim Venture Fund
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series A | •••••• | 5 |
|
14 Mar 2024 |
| Seed Round | •••••• | 3 |
|
09 Nov 2021 |
| Venture Round | •••••• | 1 | •••• •••• | 08 Sep 2020 |
Latest News
View All
Asgard Therapeutics Alternatives & Competitors
Developing Novel Therapies to Destroy Cancer
FAQ About Asgard Therapeutics
Don't just browse. Track.
Signal Tracker monitors Asgard Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.